Medamicus/Biomec
This article was originally published in The Gray Sheet
Executive Summary
Cardiac rhythm management and neuromodulation device lead and accessory supplier Biomec Cardiovascular, Inc. (BCI) will be acquired by percutaneous delivery system maker Medamicus for $18 mil. in cash and stock under a July 22 agreement. The deal will expand Medamicus' technology and OEM customer base, which includes Guidant, Medtronic, St. Jude, Cook and Bard. BCI sales "more than doubled" to $4.5 mil. for the first half of 2003, Medamicus notes. The firm simultaneously reported its second quarter sales from continuing operations of $4.3 mil., off 1%, in part due to decreased sales of advanced delivery systems. Trouble with the resin used in FlowGuard valved introducers also led the firm to suspend shipments of the device during the quarter; a re-launch is not expected until "late in the fourth quarter or early 2004," Medamicus says...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.